Juan Manuel Racosta and Marcelo Kremenchutzky
Autonomic Nervous System (ANS) dysfunction (AuD) is a common cause of disability in people living with
Multiple Sclerosis (MS), but clinical manifestations are heterogeneous and therapeutic options are lacking. AuD is
implicated as having a possible role in the regulation of inflammation and neurodegeneration. Hence, treatments
with drugs that affect the ANS may have an impact in the inflammatory and neurodegenerative processes intrinsic to
MS, resulting in an intriguing and potentially significant novel therapeutic consideration. Additionally, just alike
patients with most other chronic diseases, MS patients often are exposed to a broad range of treatments both
disease-specific and due to complications or co-morbidities. Considering them into an integrated context affords the
opportunity to understand and exploit their therapeutic potential.
